Single-center retrospective study of real-world cardiotoxicity with encorafenib and binimetinib for metastatic melanoma

Modern therapies with encorafenib and binimetinib for metastatic melanoma have significantly improved oncologic outcomes but are associated with cardiovascular risk in clinical studies. A retrospective study at Copenhagen University Hospital (Denmark) investigated this risk in clinical practice. The study included 108 patients receiving encorafenib and binimetinib for metastatic melanoma between 2019 and 2022. Minor cardiotoxicity (LVEF decline by more than 15 percentage points but remaining above 50%) was seen in 18% of patients, while major cardiotoxicity (LVEF decline by more than 10 percentage point to below 50%) was seen in 6% of patients, with intervention required in 2%. No significant declines in LVEF were seen after six months of treatment. The authors conclude that treatment with encorafenib plus binimetinib for metatatic melanoma resulted in major cardiotoxicity in 6% of patients, mostly asymtomatic and reversible, and that monitoring